Michael Farrell - ResMed Insider

ResMed Inc -- USA Stock  

USD 88.68  0.11  0.12%

CEO and Director

Mr. Michael Farrell is Chief Executive Officer and Director of the company. Mr. Farrell was our chief executive officer and a director since March 1, 2013. Before that appointment, he served as our president Americas from May 2011 our senior vice president, strategic business unit sleep from July 2007 to May 2011 our vice president, marketing for the Americas from June 2005 through July 2007 and before that was our vice president, business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and steel manufacturing at Arthur D. Little, Genzyme Corporationrationration, Dow Chemical, and BHP Billiton. Mr. Farrell serves on the board of directors of Zimmer Biomet, a multibillion dollar public company that provides implantable musculoskeletal medical devices for patients globally. Mr. Farrell is a member of the Compensation and Management Development committee as well as the Nominating and Governance committee at Zimmer Biomet. Mr. Farrell also serves on the board of directors of the Advanced Medical Technology Association, based in Washington, DC. Mr. Farrell volunteers as a trustee for nonprofit organizations UC San Diego Foundation, Rady Childrens Hospital, the La Jolla Playhouse, and the Museum of Man
Age: 44  CEO Since 2013  MBA    
858 836-5000  www.resmed.com
Farrell holds a bachelor of engineering, with firstclass honours, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management.

Michael Farrell Latest Insider Activity

Management Efficiency

The company has Return on Asset of 8.72 % which means that on every $100 spent on asset it made $8.72 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 18.43 % implying that it generated $18.43 on every 100 dollars invested.
The company has 1.02 B in debt with debt to equity (D/E) ratio of 49.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed Inc has Current Ratio of 4.63 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Found 7 records

CEO Since

Robert WeissThe Cooper Companies Inc
Paul RemmellThe Cooper Companies Inc
Michael MahoneyBoston Scientific Corporation
Kevin SayerDexCom Inc
Stephen RusckowskiQuest Diagnostics Incorporated

Entity Summary

ResMed Inc. designs, develops, manufactures, and markets medical devices and cloudbased software applications that diagnose, treat, and manage respiratory disorders. ResMed Inc (RMD) is traded on New York Stock Exchange in USA. It is located in CALIFORNIA, U.S.A and employs 5,250 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

Did you try this?

Run Premium Stories Now

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Hide  View All  NextLaunch Premium Stories
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ResMed Inc to your portfolio

Top Management

ResMed Inc Leadership Team
John Wareham, Director, MBA
Ronald Taylor, Director
Gary Pace, Director, Ph.D
Agnes Lee, Director
Carol Burt, Director
Rich Sulpizio, Director
Peter Farrell, Chairman, Ph.D
Jim Hollingshead, President, Ph.D
Don Darkin, President
Jack Wareham, Director
Anne Reiser, President
Karen Drexler, Director
Richard McHale, President
Donald Darkin, President
Rob Douglas, President
Christopher Roberts, Director, MBA
Chris Roberts, Director, MBA
Robert Douglas, COO
BE Farrell, Chairman
Brett Sandercock, CFO
Ron Taylor, Director
Raj Sodhi, President, MBA
David Pendarvis, Executive
Richard Sulpizio, Director
Michael Farrell, CEO, MBA

Stock Performance

ResMed Performance Indicators